Evidence map›Paper›PMID 42622648›Full record

ReviewInnere Medizin (Heidelberg, Germany)2026

[Multidrug resistance and new anti-infective agents].

Katja Schneider, Stefan Hagel, Maria J G T Vehreschild, Sören Gatermann, Beatrice Grabein, Jessica Rademacher, Mathias W Pletz

Abstract readReviewEnglish Abstract
PubMed Publisher
In one paragraph

Review in Innere Medizin (Heidelberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Katja SchneiderInstitut für Infektionsmedizin und Krankenhaushygiene, Universitätsklinikum Jena, Friedrich-Schiller-Universität Jena, Am Klinikum 1, 07747, Jena, Deutschland.
Stefan HagelInstitut für Infektionsmedizin und Krankenhaushygiene, Universitätsklinikum Jena, Friedrich-Schiller-Universität Jena, Am Klinikum 1, 07747, Jena, Deutschland.
Maria J G T VehreschildMedizinische Klinik 2, Infektiologie, Universitätsklinikum Frankfurt, Goethe-Universität Frankfurt, Frankfurt am Main, Deutschland.
Sören GatermannAbteilung für Medizinische Mikrobiologie, Ruhr-Universität Bochum, Bochum, Deutschland.
Beatrice GrabeinKlinische Mikrobiologie und Krankenhaushygiene, LMU Klinikum München, München, Deutschland.
Jessica RademacherKlinik für Pneumologie und Infektiologie, Medizinische Hochschule Hannover, Hannover, Deutschland.
Mathias W PletzInstitut für Infektionsmedizin und Krankenhaushygiene, Universitätsklinikum Jena, Friedrich-Schiller-Universität Jena, Am Klinikum 1, 07747, Jena, Deutschland. mathias.pletz@med.uni-jena.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multidrug-resistant pathogens are among the greatest global health threats. Among Gram-negative pathogens, the worldwide rise in carbapenem resistance is of particular clinical significance; among Gram-positive pathogens, methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci are of primary concern. Resistance mechanisms include changes in penicillin-binding proteins, enzymatic inactivation by β‑lactamases, porin modifications, and efflux pumps. Targeted therapy for infections caused by multidrug-resistant pathogens requires knowledge of the resistance mechanism and a phenotypic antibiotic susceptibility profile. New β‑lactam/β-lactamase inhibitor combinations have largely replaced older therapeutic approaches such as colistin for infections caused by multidrug-resistant Gram-negative pathogens due to their superior efficacy and tolerability. The recently published first German S3 guideline, "Antibiotic Therapy for Severe Infections Caused by Multidrug-Resistant Bacteria," provides practice-oriented treatment recommendations for infections caused by multidrug-resistant pathogens.

Indexed as

Anti-Bacterial AgentsAnti-Infective AgentsDrug Resistance, Multiple, Bacterialbeta Lactam AntibioticsCarbapenemsGram-Negative Bacterial InfectionsGram-Positive Bacterial InfectionsHumansMethicillin-Resistant Staphylococcus aureusAnti-Bacterial AgentsAnti-Infective Agentsbeta Lactam AntibioticsCarbapenemsCarbapenem resistanceMethicillin-resistant Staphylococcus aureusMultidrug-resistant pathogensResistance mechanismsVancomycin-resistant enterococci

Identifiers

PMID42622648

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.